Booster Injections after Natural Immunity of Little Value
VENUS Study Demonstrates Unacceptably Low Vaccine Efficacy in Population with Prior COVID-19 Infection
By Peter A. McCullough, MD, MPH
COVID-19 vaccination was originally indicated to prevent the first case of SARS-CoV-2 infection. As vaccine mania set in across the globe, more and more patients who already recovered from the infection accepted multiple injections with the hope of “extra protection” or as a result of vaccine mandates.
Is it possible that repeated vaccine injections confer significant benefit in those with natural immunity? Tamada et al reported from the VENUS study carried out in Japan that additional boosters on top of natural immunity had very little value. The calculated vaccine efficacy was well below 50% for any episode of COVID-19 test positivity and there was no report of hospitalization or death benefit.
All of the vaccine manufacturers excluded patients with natural immunity from prior infection for a reason, they had little or no chance of benefit and a considerable opportunity for worsened side effects. While Tamada did not report on side effects, one would conclude in populations where >90% of patients have had COVID-19, vaccination offers little value.
Courageous Discourse™ with Dr. Peter McCullough & John Leake is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.
Please subscribe to Courageous Discourse as a paying or founder member so we can continue to bring you the truth.
Peter A. McCullough, MD, MPH
President, McCullough Foundation
Tamada Y, Takeuchi K, Kusama T, Maeda M, Murata F, Osaka K, Fukuda H. Effectiveness of COVID-19 vaccines against infection in Japan: A test-negative study from the VENUS study. Vaccine. 2023 Aug 23;41(37):5447-5453. doi: 10.1016/j.vaccine.2023.07.035. Epub 2023 Jul 22. PMID: 37487845.